Pfizer entered into settlement agreements last year with a number of law firms, including our firm, to resolve many of their Bextra/Celebrex clients’ claims. Our firm represented approximately 1400 clients in this litigation. Our lawyers and staff have been working diligently over the past several months to comply with the specific requirements of the agreement. All the claims had to be evaluated, the agreement terms explained to clients and documents gathered to submit by a set deadline.
Our clients’ documents were provided to Pfizer in a timely fashion on July 1st by our lawyers and staff personnel. Once all of the information is verified and confirmed, the parties to the settlement will agree to release the settlement funds in order that compensation can be paid to qualifying clients. Our firm has been involved in this litigation for the last four to five years and we hope to be able to conclude this matter and pay compensation to our clients this fall.
As you will recall, Bextra was pulled from the market for having an increased risk of heart attacks and for causing a skin reaction called Stevens-Johnson Syndrome. While higher doses of Celebrex are no longer available on the market, the Celebrex 200mg dose is still available for sale. The FDA now requires that all NSAID medications, including this dose of Celebrex, carry a warning about increased risk of heart attacks.
If you have any questions about any of the above, contact Frank Woodson at 800-898-2034 or Frank.Woodson@beasleyallen.com.
Contact us today for a free legal consultation with an experienced attorney.
Fields marked *may be required for submission.
If you would like to subscribe to the Jere Beasley Report digital edition, simply visit our Subscriptions page and provide the necessary information or call us at 800-898-2034.
Attorney Advertising - Prior results do not guarantee a similar outcome.